• Isconova AB, of Uppsala, Sweden, said its partner, the Jenner Institute at Oxford University, received approval from the UK's Medicines and Healthcare products Regulatory Agency to start a Phase I study of a malaria vaccine candidate containing Isconova's adjuvant Matrix-M.